Structural basis of mutant-selectivity and drug-resistance related to CO-1686.
about
Structural insights into drug development strategy targeting EGFR T790M/C797S.L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib.Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor
P2860
Structural basis of mutant-selectivity and drug-resistance related to CO-1686.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Structural basis of mutant-selectivity and drug-resistance related to CO-1686.
@en
type
label
Structural basis of mutant-selectivity and drug-resistance related to CO-1686.
@en
prefLabel
Structural basis of mutant-selectivity and drug-resistance related to CO-1686.
@en
P2093
P2860
P356
P1433
P1476
Structural basis of mutant-selectivity and drug-resistance related to CO-1686.
@en
P2093
Cai-Hong Yun
Hwan Geun Choi
Ling Liang
Su-Jie Zhu
Xiao-E Yan
P2860
P304
53508-53517
P356
10.18632/ONCOTARGET.18588
P407
P577
2017-06-21T00:00:00Z